BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 05/20/24

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn PR Newswire The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, see...

2024-05-15 09:45:59 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics ...

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® C...

A look at the top 10 most actives in the United States Tilray Brands Inc. (TLRY) rose 39.5% to $2.47 on volume of 149,005,559 shares Tesla Inc. (TSLA) fell 5.6% to $183.28 on volume of 125,934,900 shares PROSHARES TRUST (SQQQ) rose 5.7% to $11.95 on volume of 124,394,426 shares Jaguar H...

2024-04-17 03:25:55 ET More on BrainStorm Cell Therapeutics BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics His...

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegener...

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS PR Newswire NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes ...

2024-04-09 07:13:19 ET DENVER, Colo., Apr 09, 2024 ( 247marketnews.com )- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI ) stated that the U.S. Food and Drug Administration (FDA) provided written approval, under a Special Protocol Assessment (SPA), on the design for a Phase 3b tria...

2024-04-09 06:58:24 ET More on BrainStorm Cell Therapeutics BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial ...